Literature DB >> 20168083

miRNAs and cancer: New research developments and potential clinical applications.

Ayse E Erson1, Elizabeth M Petty.   

Abstract

miRNAs are small non-protein coding transcripts that regulate gene expression post-transcriptionally by binding to the 3' UTRs (untranslated regions) of messenger RNAs (mRNAs). The number of newly discovered miRNAs and our understanding of their biological roles continue to grow. In addition to their roles in important biological processes such as development, differentiation, proliferation and cell death, deregulated expression of miRNAs has been implicated in a wide range of pathologies, especially in cancer. We now understand that miRNA expression is often deregulated in cancer cells and that a vast number of genes, including tumor suppressor genes and oncogenes, are regulated by these small RNAs. The small size of miRNAs and sequence similarity of miRNA family members pose some challenges in routine molecular detection and quantification techniques. Therefore, methods are being modified to specifically and sensitively detect miRNAs in cancer cells. Our current knowledge and the ever increasing pace of new discoveries clearly show that miRNAs are quite important in normal and in cancer cells in surprisingly diverse aspects. The better we understand how miRNAs contribute to cancer, the more likely we will be able to exploit them as tumor classifiers, biomarkers and, potentially, as unique targets for therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20168083     DOI: 10.4161/cbt.8.24.10765

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  13 in total

1.  ARID3B expression in primary breast cancers and breast cancer-derived cell lines.

Authors:  Ayse Selcen Oguz Erdogan; Nihan Ozdemirler; Merve Oyken; Murat Alper; Ayse Elif Erson-Bensan
Journal:  Cell Oncol (Dordr)       Date:  2014-08-14       Impact factor: 6.730

Review 2.  Optical imaging for stem cell differentiation to neuronal lineage.

Authors:  Do Won Hwang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2012-01-04

3.  ALCAM is indirectly modulated by miR-125b in MCF7 cells.

Authors:  H Begum Akman; S Duygu Selcuklu; Mark T A Donoghue; Shiva Akhavantabasi; Aysegul Sapmaz; Charles Spillane; M Cengiz Yakicier; A Elif Erson-Bensan
Journal:  Tumour Biol       Date:  2014-12-25

4.  miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells.

Authors:  Ping Liu; Michael J Wilson
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

5.  Dysregulated expression of dicer and drosha in breast cancer.

Authors:  Min Yan; Hong-Yan Huang; Ting Wang; Yi Wan; Shu-De Cui; Zhen-Zhen Liu; Qing-Xia Fan
Journal:  Pathol Oncol Res       Date:  2011-09-07       Impact factor: 3.201

6.  Complexity in regulation of microRNA machinery components in invasive breast carcinoma.

Authors:  Sun Young Kwon; Jae-ho Lee; Bora Kim; Jong-Wook Park; Taeg Kyu Kwon; Sun Hee Kang; Shin Kim
Journal:  Pathol Oncol Res       Date:  2014-02-27       Impact factor: 3.201

7.  MiR-21 suppresses the anticancer activities of curcumin by targeting PTEN gene in human non-small cell lung cancer A549 cells.

Authors:  W Zhang; W Bai; W Zhang
Journal:  Clin Transl Oncol       Date:  2013-11-29       Impact factor: 3.405

8.  Clarifying mammalian RISC assembly in vitro.

Authors:  Grace S Tan; Barry G Garchow; Xuhang Liu; David Metzler; Marianthi Kiriakidou
Journal:  BMC Mol Biol       Date:  2011-04-29       Impact factor: 2.946

Review 9.  The role of hypoxia-induced miR-210 in cancer progression.

Authors:  Kyvan Dang; Kenneth A Myers
Journal:  Int J Mol Sci       Date:  2015-03-19       Impact factor: 5.923

10.  New biomarkers in peripheral blood of patients with ovarian cancer: high expression levels of miR-16-5p, miR-17-5p, and miR-638.

Authors:  Mukaddes Avsar Saral; Seref Bugra Tuncer; Demet Akdeniz Odemis; Ozge Sukruoglu Erdogan; Seda Kilic Erciyas; Pınar Saip; Sevda Ozel; Hulya Yazici
Journal:  Arch Gynecol Obstet       Date:  2021-08-09       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.